Abstract:7035 Background: Patients with specific mutations in EGFR likely receive more benefit from EGFR TKI therapy. Here we evaluated the utility of EGFR mutation-specific antibodies in primary tumors for screening of EGFR-mutant NSCLC patients in comparison with a sequencing method. Methods: Immunohistochemistry (IHC) were performed on formalin-fixed, paraffin-embedded samples from primary lesions of 103 NSCLC patients, using antibodies against to wild-type EGFR, dEGFR (E746-A750 del) and L858R EGFR on the serial sections. Tumors with IHC scores of 1+ to 3+ scores were interpreted as IHC positive, and tumors with 0 score were considered as negative. Each of these samples was also subjected to direct sequencing for EGFR mutation status. Results: 27 of 103 cases were detected as EGFR E746-A750 del and L858R mutation by sequencing. Among the 13 EGFR E746-A750 del samples detected by sequencing, 11 of them were also scored IHC positive, with a sensitivity of 85% for the dEGFR antibody as compared with the direct sequencing method. In the rest of 90 cases which were negative for EGFR E746-A750 del by sequencing, the anti-dEGFR antibody detected 2 positive with a specificity of 98%. The anti-L858R EGFR antibody detected 9 positive out of 14 L858R mutation cases by sequencing, with a sensitivity of 64%. In the other 89 cases which were negative for L858R mutation by sequencing, the anti-L858R EGFR antibody detected 5 positive with a specificity of 94%. In combination of the results from both antibodies, the overall sensitivity of the IHC method was 74% (20/27), and the specificity was 92% (70/76) as compared with the direct sequencing method. In addition, sequencing showed several EGFR mutations other than dEGFR or L858R in 12 cases. None of these 12 cases were detected positive by using the two IHC antibodies. Conclusions: Given over 90% specificity, our results suggested IHC using the two mutation specific antibodies could be an ancillary method for EGFR mutation screening in the NSCLC patients, especially when there is not enough tumor tissues for sequencing detection. The utility of the IHC method with mutation-specific antibodies would need further validation in clinical studies.

Evaluation of the Idylla™ EGFR Mutation Test on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

Application of IdyllaTM System for Rapid Evaluation of EGFR Mutation Status in Formalin-Fixed and Paraffin-Embedded Samples of Non-Small Cell Lung Cancer.

Evaluation of the IdyllaTM EGFR Mutation Test on formalin-fixed, paraffin-embedded tissue of human lung cancer

Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day

Ultra-rapid Idylla? <i>EGFR</i> mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer

Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Detection of Epidermal Growth Factor Receptor Mutations in Small Specimens of Non-Small Cell Lung Cancer by Amplification Refractory Mutation System

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

Comparison of Cross-Platform Technologies for EGFR T790M Testing in Patients with Non-Small Cell Lung Cancer

RET Fusion Detection Using IdyllaTM Gene Fusion Assay

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma

Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the IdyllaTM platform: a real-world two-center experience in Greece

Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study

Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma

A Comparison of ARMS and Direct Sequencing for EGFR Mutation Analysis and Tyrosine Kinase Inhibitors Treatment Prediction in Body Fluid Samples of Non-Small-Cell Lung Cancer Patients

ARMS for EGFR Mutation Analysis of Cytologic and Corresponding Lung Adenocarcinoma Histologic Specimens

Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR

Detection of Egfr Mutations with Mutation-Specific Antibodies in Primary Lesions of Non-Small Cell Lung Cancer